Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
Philippe Bégin, Jeannie Callum, Erin Jamula, Richard Cook, Nancy M Heddle, Alan Tinmouth, Michelle P Zeller, Guillaume Beaudoin-Bussières, Luiz Amorim, Renée Bazin, Kent Cadogan Loftsgard, Richard Carl, Michaël Chassé, Melissa M Cushing, Nick Daneman, Dana V Devine, Jeannot Dumaresq, Dean A Fergusson, Caroline Gabe, Marshall J Glesby, Na Li, Yang Liu, Allison McGeer, Nancy Robitaille, Bruce S Sachais, Damon C Scales, Lisa Schwartz, Nadine Shehata, Alexis F Turgeon, Heidi Wood, Ryan Zarychanski, Andrés Finzi, CONCOR-1 Study Group, Donald M Arnold
Abstract
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content could influence patient outcomes. We conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset ( NCT04348656 ). Patients were allocated 2:1 to 500 ml of convalescent plasma or standard of care. The composite primary outcome was intubation or death by 30 d. Exploratory analyses of the effect of convalescent plasma antibodies on the primary outcome was assessed by logistic regression. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility. In total, 940 patients were randomized, and 921 patients were included in the intention-to-treat analysis. Intubation or death occurred in 199/614 (32.4%) patients in the convalescent plasma arm and 86/307 (28.0%) patients in the standard of care arm-relative risk (RR) = 1.16 (95% confidence interval (CI) 0.94-1.43, P = 0.18). Patients in the convalescent plasma arm had more serious adverse events (33.4% versus 26.4%; RR = 1.27, 95% CI 1.02-1.57, P = 0.034). The antibody content significantly modulated the therapeutic effect of convalescent plasma. In multivariate analysis, each standardized log increase in neutralization or antibody-dependent cellular cytotoxicity independently reduced the potential harmful effect of plasma (odds ratio (OR) = 0.74, 95% CI 0.57-0.95 and OR = 0.66, 95% CI 0.50-0.87, respectively), whereas IgG against the full transmembrane spike protein increased it (OR = 1.53, 95% CI 1.14-2.05). Convalescent plasma did not reduce the risk of intubation or death at 30 d in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care.
Conflict of interest statement
The authors declare no competing interests.
© 2021. The Author(s).
Figures
References
- Seow J, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 2020;5:1598–1607. doi: 10.1038/s41564-020-00813-8.
- Devasenapathy N, et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis. CMAJ. 2020;192:E745–E755. doi: 10.1503/cmaj.200642.
- Wood EM, Estcourt LJ, McQuilten ZK. How should we use convalescent plasma therapies for the management of COVID-19? Blood. 2021;137:1573–1581. doi: 10.1182/blood.2020008903.
- Blackall D, et al. Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network. Transfusion. 2020;60:2203–2209. doi: 10.1111/trf.16026.
- Simonovich VA, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N. Engl. J. Med. 2021;384:619–629. doi: 10.1056/NEJMoa2031304.
- Agarwal A, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) Brit. Med. J. 2020;371:m3939. doi: 10.1136/bmj.m3939.
- Li L, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:460–470. doi: 10.1001/jama.2020.10044.
- Piechotta V, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst. Rev. 2021;5:CD013600.
- Joyner MJ, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N. Engl. J. Med. 2021;384:1015–1027. doi: 10.1056/NEJMoa2031893.
- The RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet397, 2049–2059 (2021).
- Ray, Y. et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. Preprint at (2020).
- Gharbharan A, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat. Commun. 2021;12:3189. doi: 10.1038/s41467-021-23469-2.
- Libster R, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N. Engl. J. Med. 2021;384:610–618. doi: 10.1056/NEJMoa2033700.
- O’Donnell, M. R. et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J. Clin. Invest. 131, e150646 (2021).
- Avendaño-Solà, C. et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. Preprint at (2020).
- Estcourt, L. J. Convalescent plasma in critically ill patients with Covid-19. Preprint at (2021).
- Bennett-Guerrero, E. et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in Coronavirus Disease 2019 infected hospitalized patients in New York: a double-blind randomized trial. Crit. Care Med. 49, 1015–1025 (2021).
- Körper, S. et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. Preprint at (2021).
- AlQahtani M, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Sci. Rep. 2021;11:9927. doi: 10.1038/s41598-021-89444-5.
- Hamdy Salman O, Ail Mohamed HS. Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egypt. J. Anaesth. 2020;36:264–272. doi: 10.1080/11101849.2020.1842087.
- Bajpai, M. et al. efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Preprint at (2020).
- Winkler ES, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184:1804–1820. doi: 10.1016/j.cell.2021.02.026.
- Suryadevara N, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021;184:2316–2331. doi: 10.1016/j.cell.2021.03.029.
- Ullah, I. et al. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy. Preprint at (2021).
- Schafer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. 218, e20201993 (2021).
- Brunet-Ratnasingham, E. A. S. et al. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Preprint at (2021).
- Zohar T, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell. 2020;183:1508–1519. doi: 10.1016/j.cell.2020.10.052.
- Casadevall A, Joyner MJ, Pirofski LA. Neutralizing antibody LY-CoV555 for outpatient Covid-19. N. Engl. J. Med. 2021;384:189. doi: 10.1056/NEJMc2033787.
- Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012;366:1275–1286. doi: 10.1056/NEJMoa1113425.
- Tomaras GD, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl Acad. Sci. USA. 2013;110:9019–9024. doi: 10.1073/pnas.1301456110.
- Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J. Immunol. 2003;170:3621–3630. doi: 10.4049/jimmunol.170.7.3621.
- Hamilton FW, Lee T, Arnold DT, Lilford R, Hemming K. Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial. Int. J. Infect. Dis. 2021;109:114–117. doi: 10.1016/j.ijid.2021.06.034.
- Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52:160–165. doi: 10.1111/j.1537-2995.2011.03247.x.
- Begin P, et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials. 2021;22:323. doi: 10.1186/s13063-021-05235-3.
- Harris PA, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009;42:377–381. doi: 10.1016/j.jbi.2008.08.010.
- Budhai A, et al. How did we rapidly implement a convalescent plasma program? Transfusion. 2020;60:1348–1355. doi: 10.1111/trf.15910.
- Abe, K. T. et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight. 5, e142362 (2020).
- Mendoza EJ, Manguiat K, Wood H, Drebot M. Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2. Curr. Protoc. Microbiol. 2020;57:ecpmc105.
- Beaudoin-Bussieres, G. et al. Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. Preprint at (2020).
- Perreault J, et al. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood. 2020;136:2588–2591. doi: 10.1182/blood.2020008367.
- Anand, S. P. et al. High-throughput detection of antibodies targeting the SARS-CoV-2 spike in longitudinal convalescent plasma samples. Transfusion61, 1377–1382 (2021).
- Tauzin, A. N. M. et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. Preprint at (2021).
- Anand, S. P. et al. Longitudinal analysis of humoral immunity against SARS-CoV-2 spike in convalescent individuals up to eight months post-symptom onset. Cell Rep. Med. 2, 100290 (2021).
- Wood, S. N. Generalized Additive Models: An Introduction with R, Second Edition (Taylor and Francis, 2017).
- O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556. doi: 10.2307/2530245.
- R Development Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2010).
- Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. J. R. Stat. Soc. Ser. B (Methodol.) 2011;73:3–36. doi: 10.1111/j.1467-9868.2010.00749.x.
Source: PubMed